



## Severe Asthma: From Bench to Bedside

Guest Editors:

**Dr. Marco Bonavia**

Pulmonary Rehabilitation Center  
in Colletta Hospital, Genoa, Italy

**Prof. Dr. Manlio Milanese**

Division of Pneumology,  
S. Corona Hospital, Pietra Ligure,  
Italy

Deadline for manuscript  
submissions:

**closed (31 October 2023)**

### Message from the Guest Editors

Dear Colleagues,

Biologics have proven efficient for treating T2 Severe Asthma, and biologic therapies improve patients' quality of life of patients far more than was observable in RCTs.

With the implementation of these treatments, new questions have arisen. Can biologics temporarily or permanently modify the immunologic pattern of patients? How much do we know about eosinophils in the blood vs. those in the tissues? When we try to define absent vs. partial vs. complete response to biological therapies, do we refer to a clinical, or laboratory tool (or both)? Once we have identified the best treatment method (IL5, for example), how do the others contribute toward downregulation or compensative upregulation? Can the Pulmonary Function Test be used to stratify severe asthmatic patients? In the relatively small cohort of not T2 Severe Asthma, when do we expect to discover effective new therapeutical agents? Do the nose and bronchi always show similar responses to Biologics?

We hope to explore these and other topics related to Severe Asthma from both theoretical and clinical perspectives.

Dr. Marco Bonavia

Prof. Dr. Manlio Milanese

*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research

Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA

2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)